VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2019 | Novel agents in CLL: acalabrutinib and zanubrutinib

Barbara Eichhorst
EHA 2019
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Ibrutinib Zanubrutinib
ALPINE ASCEND

Barbara Eichhorst, MD, from the University Hospital of Cologne, Cologne, Germany, discusses the data so far for acalabrutinib and zanubrutinib, novel BTK inhibitors for chronic lympocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Barbara Eichhorst

2:12
Can chemoimmunotherapy in CLL treatment be replaced with novel agents?
Barbara Eichhorst • 22 Jun 2017
15:21
MRD assessment and the treatment of patients in the 'real world'
Arnon Kater et al. • 20 Sep 2019
1:18
ASH 2017: combination therapy for CLL highlights
Barbara Eichhorst • 9 Dec 2017
2:24
Interim analysis of the ALPINE study
Barbara Eichhorst • 6 Sep 2021

Related Videos

1:41
Key challenges of using the intestinal microbiome as a biomarker
Melody Smith
1:32
CAR T-cell therapy: the importance of LTFU
Graham Collins
1:44
The future of AML therapy
Andreas Burchert
0:42
Treating pediatric patients with hematological malignancies
Claudia Rössig
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals